Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers  

作　　者：Minoru Tada Yousuke Nakai Takashi Sasaki Tsuyoshi Hamada Rie Nagano Dai Mohri Koji Miyabayashi Keisuke Yamamoto Hirofumi Kogure Kazumichi Kawakubo Yukiko Ito Natsuyo Yamamoto Naoki Sasahira Kenji Hirano Hideaki Ijichi Keishuke Tateishi Hiroyuki Isayama Masao Omata Kazuhiko Koike 

机构地区：[1]Department of Gastroenterology,Graduate School of Medicine,The University of Tokyo,Tokyo 113-8655,Japan [2]Yamanashi Prefectural Hospital Organization,400-8506 Yamanashi,Japan

出　　处：《World Journal of Clinical Oncology》2011年第3期158-163,共6页世界临床肿瘤学杂志（英文版）

摘　　要：Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade.New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs.Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival,although the effect was minimal.Little or no improvement in survival with recent moleculartargeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer.Recently,the non-gemcitabine-based-regimen of FOLFIRINOX showed significantly greater overall survival compared with gemcitabine for the first time.For biliary tract cancer,gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy.Further improvement in survival is expected by the addition of cetuximab.

关 键 词：CISPLATIN EPIDERMAL growth factor receptor GEMCITABINE K-RAS S-1 

分 类 号：R[医药卫生]